L01EA05 - search results

iclusig tablet

takeda pharmaceuticals u.s.a., inc. - ponatinib (ponatinib hydrochloride) - tablet - 15mg - ponatinib (ponatinib hydrochloride) 15mg - antineoplastic agents

Canada - English - Health Canada

iclusig tablet

takeda pharmaceuticals u.s.a., inc. - ponatinib (ponatinib hydrochloride) - tablet - 45mg - ponatinib (ponatinib hydrochloride) 45mg - antineoplastic agents

Singapore - English - HSA (Health Sciences Authority)

iclusig tablet 15 mg

steward cross pte ltd - ponatinib hcl eqv ponatinib - tablet, film coated - ponatinib hcl eqv ponatinib 15 mg

Singapore - English - HSA (Health Sciences Authority)

iclusig tablet 45 mg

steward cross pte ltd - ponatinib hcl eqv ponatinib - tablet, film coated - ponatinib hcl eqv ponatinib 45 mg

European Union - English - EMA (European Medicines Agency)

iclusig

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.see sections 4.2 assessment of cardiovascular status prior to start of therapy and 4.4 situations where an alternative treatment may be considered.